In a report released on August 7, Puneet Souda from Leerink Partners maintained a Buy rating on Myriad Genetics (MYGN – Research Report), with a price target of $35.00. Puneet Souda has given his Buy ...
SALT LAKE CITY, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the substantial completion of its strategic ...
These mutations improve biocontainment, transformation stability, and overall performance in genetic engineering of plants. Complementing the strains, researchers also developed new plasmids and a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback